1. Liu, Xinwei, Lu, Yiwen, Huang, Jingying, Gu, Yuanting, Su, Shicheng. . CD16+ fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibition. In Cancer cell, 40, 1341-1357.e13. doi:10.1016/j.ccell.2022.10.015. https://pubmed.ncbi.nlm.nih.gov/36379207/
2. Lorenzo-Martín, Luis Francisco, Menacho-Márquez, Mauricio, Bustelo, Xosé R. 2020. Drug Vulnerabilities and Disease Prognosis Linked to the Stem Cell-Like Gene Expression Program Triggered by the RHO GTPase Activator VAV2 in Hyperplastic Keratinocytes and Head and Neck Cancer. In Cancers, 12, . doi:10.3390/cancers12092498. https://pubmed.ncbi.nlm.nih.gov/32899210/
3. Liu, Weiling, Miao, Chuanwang, Zhang, Shaosen, Lin, Dongxin, Wu, Chen. 2021. VAV2 is required for DNA repair and implicated in cancer radiotherapy resistance. In Signal transduction and targeted therapy, 6, 322. doi:10.1038/s41392-021-00735-9. https://pubmed.ncbi.nlm.nih.gov/34462423/
4. Tan, Bi-Bo, Li, Yong, Fan, Li-Qiao, Wang, Dong, Jia, Nan. . Upregulated Vav2 in gastric cancer tissues promotes tumor invasion and metastasis. In Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 39, 1010428317698392. doi:10.1177/1010428317698392. https://pubmed.ncbi.nlm.nih.gov/28459214/
5. Zhou, Tianxing, Hou, Xupeng, Yan, Jingrui, Liu, Jing, Hao, Jihui. 2024. CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-like CD8+ T cells. In Gut, 73, 1984-1998. doi:10.1136/gutjnl-2024-332371. https://pubmed.ncbi.nlm.nih.gov/39187291/
智鼠故事 
